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5. Immunology pulmonology 
~ Delivery of tobramycin via the I-neb TM Adaptive Aerosol Delivery 
(AAD ®) system and the Pari LC Plus ® nebulizer 
L.E. Hardaker, R.W Potter, E.A. Akunda. Respironics Respiratory Drug 
Delivery (UK) Ltd, Heath Place, Bognor Regis', West Sussex, P022 9SL, UK 
Background and Aim: The suitability of the I-neb TM AAD ® System to aerosolize 
Tobramycin I halation Solution 60 mg/mL, 5 mL (TIS, Chiron UK Ltd, Hounslow, 
UK) has not been established. We compared the dose delivery of TIS via I-neb 
with that from the Pari LC Plus ® nebulizer with DeVilbiss compressor. 
Methods: Three I-neb devices fitted with metering chambers designed to deliver a 
preset dose of 1.4 mL, and three Pari nebulizers were weighed, loaded with 5 mL, 
and run on the CEN simulated breathing pattern. Aerosol was collected on a filter 
placed between aMiMiC Emulator (Respironics) and the device. Emitted ose was 
determined by gravimetric output (mg solution), and delivered ose was determined 
by both HPLC and bioassay (rag TIS). All tests were conducted in triplicate. 
Results: The mean respective mitted ose and HPLC recoveries were; 1388 mg 
and 76 mg (I-neb), compared with 3504 mg and 106 mg (Pari). The mean bioassay 
doses were equivalent to the mean HPLC doses. 
Discussion and Conclusions: As I-neb has a delivered ose of 76 mg, and AAD 
Systems have been shown to deposit 60% of the dose in the lung [1], this would 
result in a TIS lung dose of 45 rag. The Pari LC Plus has a higher delivered ose, 
but the overall ung deposition is only 15°/0 of the fill volume, i.e. 45 mg [2]. The 
results of this test suggest that in patients the lung dose would be similar for the 
two devices tested. 
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~ Pulmonary deposition of inhaled tobramycin (TOBI), 
before and after physiotherapy and inhaled salbutamol in 
cystic fibrosis (CF) patients 
M.B. Grotta 1, J. Romanato 2, E.C.S.C. Etchebehere 2, A.F. Ribeiro 1 , G. Hessel 1, 
M.A.G.O. Ribeiro 3, E.E. Camargo 2, J.D. Ribeiro 1 . 1Department ofPediatrics, 
2Department ofRadiology and Nuclear Medicine, 3Department ofPhysiotherapy, 
State University of Campinas Medical School, Unicamp, Brazil 
Patients with CF are often treated with inhaled antibiotics and physiotherapy. No 
study evaluating the pulmonary deposition of inhaled antibiotics before and after 
physiotherapy and bronchodilators has been found in literature. 
Aim: To evaluate TOBI pulmonary deposition before and after physiotherapy and 
inhaled salbutamol. 
Patients and Methods: A clinical controlled, prospective study including CF pa- 
tients colonized by P aeruginosa was done from July to November 2005. Exclusions 
criteria: pulmonary exacerbation at the scintigraphy moment, changes in medication 
between phase I and II, FEV1 <25% predicted. Pulmonary scintigraphy was 
performed in a equipped camera with a LEAP collimator that showed the lungs drug 
penetration after inhalation with technetium-99mTc marked TOBI and pulmonary 
perfusion with albumin99mTc (phase I). Phase II: after physiotherapy with flutter, 
the same procedure was done in all patients one month later. The efficiency of 
marked TOBI-99mTc was 87%. 
Results: 24 patients (12 males). Mean age (12.85 SD 6.64) ranged from 5 27 years. 
TOBI pulmonary deposition was lower at the phase II in total lungs: p 0.006, right 
lung: p 0.003, left lung: p 0.016, anterior ight lung: p 0.004; posterior ight 
lung p 0.003; anterior left lung: p 0.011; posterior left lung: p 0.025, when 
compared to phase h 
Conclusion: Physiotherapy with flutter and inhaled salbutamol, immediately before 
TOBI inhalation makes the TOBI pulmonary deposition less efficient in CF patients. 
• Itraconazole monotherapy for allergic bronchopulmonary 
aspergillosis in cystic fibrosis (CF) 
D. T-Drinkovic, D. Tjesic-D, J. Kelecic. Department ofPediatrics, Zagreb School of 
Medicine, Croatia 
Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction to colonization 
of the lungs with Aspergillus fumigantus (Af) and affects around 10% of people 
with CE 
We report of ABPA in a 17 year old girl (dF508/K1303) with CF accompanied by 
liver cirrhosis and insulin dependant diabetes (CFRD). The criteria for ABPA were: 
increasing cough, breathlessness, occasional hemoptysis, new infiltrates on radiography 
and decline in FEV1 from 79 to 63%, with positive laboratory tests (see Table). Because 
of diabetes, steroids were not given. She was treated with itroconazole 200 mg/daily 
for 20 months. No changes in liver function tests or other side-effects were observed. 
Up till now, ABPA has not recurred (2.5 years after th). Laboratory follow up is in 
Table: 
Aj" in spuham Total IgE Aj'-IgE FEV1 (% of Skin prick test 
(kU/L) (RAST) predicted) 
Before itrocoi/azole ++ 1604 4+ 63 +++ 
2 inonths itrocoi/azole + 1196 4+ 69 +++ 
20 months itroconazole 238 3+ 79 85 ++ 
1 y after th 192 77 82 ++ 
Conclusion: At present, there are still no conclusive treatment recommendations 
for ABPA. Spontaneous resolution is possible. Nevertheless, our patient seemed to 
benefit from itroconazole monotherapy in circumstances when a complicated course 
of ABPA could be expected, due to multiple organ CF expression/complications (i.e. 
cirrhosis, CFRD, hypersplenism, hemoptysis, puberty delay, osteoporosis). Itroconazole 
monotherapy has been reported previously in a limited number of patients, as well as 
2 cases of voriconazole monotherapy recently. However, voriconazole is expensive and 
also has considerable adverse ffects. We think that itroconazole monotherapy should 
be considered as a reasonable choice of treatment when steroids are deemed unsuitable, 
especially in patients with no previous ABPA and in countries with low income. 
• Pulmonary deposition of inhaled tobramycin (TOBI), before and 
after physiotherapy and inhaled salbutamol and correlation with 
Shwachman Score (SS) in cystic fibrosis (CF) patients 
M.B. Grotta 1, J. Romanato 2, E.C.S.C. Etchebehere 2, A.F. Ribeiro 1 , G. Hessel 1, 
C.hS. Santos 3, S.R.M. Paula 3, E.E. Camargo 2, J.D. Ribeiro 1 . 1Department of
Pediatrics, 2Nuclear Medicine, 3physiotherapy, State University of Campinas 
Medical School, Unicamp, Brazil 
Patients with CF are often treated with inhaled antibiotics and physiotherapy. No 
study evaluating the pulmonary deposition of inhaled antibiotics before and after 
physiotherapy and bronchodilators has been found. 
Aim: To evaluate TOBI pulmonary deposition before and after physiotherapy and 
inhaled salbutamol and to correlate with SS. 
Methods: A clinical controlled, prospective study including CF patients colonized 
by P aeruginosa was done from July/November 2005. Exclusions criteria: pul- 
monary exacerbation at the scintigraphy moment, changes in medication between 
phase I and II, FEV1 <25% predicted. Pulmonary scintigraphy was performed 
in a equipped camera with a LEAP collimator that showed the lungs drug 
penetration after inhalation with 99mTc marked TOBI and pulmonary perfusion 
with albumin99mTc (phase I). Phase II: after physiotherapy with flutter, the same 
procedure was done in all patients one month later. The efficiency of marked TOBI- 
99mTc was 87%. The SS was classified in excellent/good; moderate/regular and 
severe. 
Results: 24 patients (12 males). Mean age (12.85 SD 6.64) ranged from 5 27 years. 
SS: excellent/good: 8 patients; moderate/regular: 16 patients. TOBI pulmonary 
deposition was lower in phase II in all pulmonary segments in CF patients with 
moderate/regular SS when compared with excellent/good SSCF patients (p 0.017). 
Conclusion: Physiotherapy with flutter and inhaled salbutamol, immediately before 
TOBI inhalation makes the TOBI pulmonary deposition less efficient in CF patients 
and has correlation with the CF severity 
